Schneider Eugene 4

What Happened
Eugene Schneider, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals (IONS), sold 5,812 shares on March 19, 2026 in an open-market/private sale. The shares were sold for a weighted-average price of $70.97, generating proceeds of approximately $412,486. This was a sale (not a purchase); sales by insiders are often routine and may be pre-planned.

Key Details

• Transaction date: 2026-03-19; Form 4 filed: 2026-03-23.
• Shares sold: 5,812; weighted-average price: $70.97; total proceeds ≈ $412,486.
• Price range reported: $70.76 to $71.375 (shares were sold in multiple transactions within this range).
• Shares owned after transaction: Not disclosed on this Form 4.
• Footnotes: (1) Sale executed pursuant to a Rule 10b5-1 trading plan adopted by Schneider on Nov 19, 2025. (2) The reported price is a weighted average; the filer will provide per-price breakdown on request.
• Filing timeliness: No late-filing flag provided in the filing data.

Context
A 10b5-1 trading plan indicates the transaction was pre-arranged and executed under a preset schedule, which can reduce the extent to which the sale reflects the insider’s current view on the stock. For retail investors, purchases often carry more direct informational weight than routine or plan-based sales.